Free Trial

CureVac (CVAC) Stock Price, News & Analysis

+0.12 (+3.27%)
(As of 07/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
722,793 shs
Average Volume
1.05 million shs
Market Capitalization
$848.51 million
P/E Ratio
Dividend Yield
Price Target

CureVac MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
163.9% Upside
$10.00 Price Target
Short Interest
6.55% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.51mentions of CureVac in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.07 to ($0.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.83 out of 5 stars

Medical Sector

351st out of 894 stocks

Pharmaceutical Preparations Industry

164th out of 426 stocks

CVAC stock logo

About CureVac Stock (NASDAQ:CVAC)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CVAC Stock Price History

CVAC Stock News Headlines

CVAC Aug 2024 2.000 put (CVAC240816P00002000)
CureVac (NASDAQ:CVAC) Shares Gap Down to $3.60
J.P. Morgan’s warns of "most predictable crisis in history"
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
J.P. Morgan’s warns of "most predictable crisis in history"
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
See More Headlines
Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$58.18 million
Book Value
$2.50 per share


Free Float
Market Cap
$832.83 million
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Alexander Zehnder M.B.A. (Age 54)
    M.D., CEO, MD & Member of Management Board
    Comp: $1.05M
  • Mr. Pierre Kemula B.Sc. (Age 49)
    MD, CFO & Member of Management Board
    Comp: $700.97k
  • Dr. Malte Greune Ph.D. (Age 59)
    COO, Member of Management Board & MD
    Comp: $643.71k
  • Dr. Myriam Mendila M.D. (Age 58)
    Chief Development Officer, MD & Member of the Management Board
    Comp: $658.44k
  • Dr. Ulrike Gnad-Vogt M.D. (Age 51)
    Ph.D., Senior VP & Area Head of Oncology
    Comp: $304.47k
  • Dr. Sarah Fakih
    Vice President Corporate Communications & Investor Relations
  • Mr. Marco Rau L.L.M.
    Ph.D., General Counsel
  • Mr. Thorsten Schuller
    Head of Corporate Communications
  • Slavica Stevanovic-Heck
    Head of Human Resources
  • Dr. Patrick Baumhof
    Senior Vice President of Technology

CVAC Stock Analysis - Frequently Asked Questions

How have CVAC shares performed this year?

CureVac's stock was trading at $4.21 on January 1st, 2024. Since then, CVAC shares have decreased by 10.0% and is now trading at $3.79.
View the best growth stocks for 2024 here

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) announced its earnings results on Thursday, May, 23rd. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.12. The company earned $13.43 million during the quarter, compared to analysts' expectations of $14.51 million. CureVac had a negative trailing twelve-month return on equity of 49.22% and a negative net margin of 463.49%.

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE) and

This page (NASDAQ:CVAC) was last updated on 7/22/2024 by Staff

From Our Partners